Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule

Next Previous
Trial Profile

A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TQB 3602 (Primary)
  • Indications Multiple myeloma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Chia Tai Tianqing Pharmaceutical Group

Most Recent Events

  • 13 Dec 2022 Status changed from recruiting to completed, according to results presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 13 Dec 2022 Results assessing safety, tolerability and pharmacokinetics of TQB3602 and assess the efficacy of TQB3602 combined with immunomodulators/dexamethasone regimen in relapsed/refractory multiple myeloma, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 17 Jun 2022 Results (N=25, between May 2020 and October 2021) presented at the 27th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top